Biocellis

Biocellis is revolutionizing biological diagnostics with a breakthrough immunoassay technology capable of delivering results in less than 60 seconds, with picogram-level sensitivity and minimal sample preparation. This innovation is based on patented research developed over more than ten years at leading French scientific institutions.

Biocellis bioluminescence technology is the result of more than a decade of interdisciplinary research conducted at leading institutions such as the Pasteur Institute, the CNRS, and Inserm. Its robustness and reliability have been recognized at the national level: it has been selected by Santé publique France to carry out more than one million epidemiological tests for the surveillance of the French population during the COVID-19 pandemic.

Protected by international patents, this technology has been validated by a multidisciplinary team of physicists, biologists, and clinicians, guaranteeing scientific rigor, clinical relevance, and industrial potential.

The project supported by ID CLUSTER aims to drastically accelerate the development of new immunoassays, reducing development times from several months to a few weeks. This strategic advance will enable faster deployment of diagnostic tests and greater adaptability in the face of health crises and future pandemics.